Liquid Biopsy: A Non-Invasive Method for Cancer Screening and Monitoring A liquid biopsy is a non-invasive medical test that analyzes blood to detect cancers and monitor their response to treatment. Rather than relying on invasive tissue biopsies, liquid biopsies detect and analyze tumor DNA, RNA or protein biomarkers that have leaked or been shed from tumor cells into the bloodstream. Liquid Biopsy collects a simple blood sample to analyze these biomarkers. Advanced molecular analyses are then used to detect the specific cancer-associated genetic mutations present in the ctDNA and other biomarkers. This tumor profiling information can indicate the location and type of a patient's primary tumor without the need for invasive tissue biopsy. Levels of circulating markers can also help clinicians monitor how a cancer responds to treatment. Liquid Biopsy- https://prachicmi.livepositively.com/liquid-biopsy-a-cutting-edge-cancer-detection-method/new=1 #CoherentMarketInsights #Exosomes&Biomarkers #Microfluidics&LabonaChipTechnology #BreastMilkCancerDiagnosis #CancerPrevalence&ResearchFunding

Advances in Cancer Treatment: The Rise of Oncology Drugs Oncology Drugs can then be selected that specifically target these aberrations, inhibiting the growth and spread of cancer cells. Examples include therapies targeting mutations in the EGFR, BRAF, ALK, and ROS1 genes. Therapies such as EGFR inhibitors have shown significant success treating lung cancers with EGFR mutations, achieving response rates over 70% in some studies. BRAF and MEK inhibitors have also had great success treating melanomas with BRAF mutations. Get more insights on, Oncology Drugs (https://www.timessquarereporter.com/business/latest-advancements-in-cancer-treatment-and-oncology-drugs) #CoherentMarketInsights #Chemotherapy #RisingCancerPrevalence #PatentExpirationsandGenericCompetition #StringentRegulatoryApprovalProcesses